Virogin Biotech Announces Dosing the First US Patient in a Phase 1 Study of VG201 for Patients With Advanced Solid Tumors
VANCOUVER, British Columbia, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Virogin Biotech, a clinical-stage biotech company, today announced that the first patient has been dosed in its Phase 1 clinical study evaluating VG201, a first-in-class HSV Type I oncolytic virus product constructed based on a transcriptional and translational dual-regulated (TTDR) backbone developed by Virogin Biotech. It is designed to generate enhanced oncolytic activity specifically for tumors expressing carcinoembryonic antigen (CEA) and is designed to produce immune-stimulating cytokines IL-12 and IL-15/IL-15Rα which, in turn, may modulate the tumor microenvironment. Furthermore, VG201 expects to be the first oncolytic virotherapy that targets tumor-specific biomarkers. The study is a first-in-human Phase 1 trial at The University of Texas MD Anderson Cancer Center evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of VG201. The trial is part of an ongoing strategic collaboration between Virogin and MD Anderson.
About Virogin Biotech:
Virogin Biotech is a clinical-stage biotech company developing next-generation immuno-oncolytic therapeutics to enhance systemic anti-tumor immunity. With over 170 employees in, Canada, China, and the United States, and led by a team with over 25 years of experience in fundamental research and translational and clinical development of immunotherapy & oncolytic virotherapy, Virogin is determined to be a global, best-in-class immuno-oncology company that creates impactful therapeutics for patients with the highest medical need.
Virogin is developing two different platforms that are highly complementary: an oncolytic HSV-1 platform armed with multiple therapeutic payloads and genomic regulation to increase oncolytic effect and modulate the tumor microenvironment; and a discovery-stage mRNA tumor vaccine platform consisting of tumor vaccines to be used in combination with oncolytic viruses to augment anti-tumor activity.
Contact Information:
Jeff Lange
EVP Business Development
partnering@virogin.com
604-222-0591
Related Images
This content was issued through the press release distribution service at Newswire.com.
Attachment
Virogin Biotech
Virogin Biotech
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
